Clinical Obesity Refines Longitudinal Risk Stratification for Liver-related and Cardiometabolic Outcomes Beyond BMI

초록

Background and Aims The Lancet Diabetes & Endocrinology Commission recently proposed a classification of obesity distinguishing preclinical from clinical obesity by integrating excess adiposity with obesity-related organ dysfunction. Whether this classification improves longitudinal risk stratification for liver-related and cardiometabolic outcomes beyond conventional body mass index (BMI)-defined obesity remains unclear. Methods We analysed 282,719 European-ancestry adults from the UK Biobank (UKBB) and 460,507 predominantly older Korean adults from the Korean National Health Insurance Service (KNHIS) Senior Cohort. Participants were classified according to BMI categories (normal weight, overweight, obesity) and Lancet Commission criteria as having no obesity, preclinical obesity, or clinical obesity. Cox models estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for incident liver-related events, cardiovascular events, and all-cause mortality. Transition from preclinical to clinical obesity was assessed in UKBB. Results In UKBB, over a median follow-up of 14.2 years, both BMI-based and Lancet Commission classifications showed a graded increase in liver-related risk. Compared with normal weight, overweight and BMI-defined obesity were associated with liver-related events with aHRs of 1.09 (95% CI 1.00–1.18; p=0.043) and 1.78 (1.63–1.94; p<0.001), respectively. Under the Lancet Commission classification, preclinical obesity showed intermediate liver-related risk (aHR 1.24, 1.14–1.35; p<0.001), while clinical obesity showed the highest risk (aHR 1.98, 1.83–2.15; p<0.001), compared with no obesity. Compared with BMI-defined obesity, clinical obesity also showed stronger associations with cardiovascular events (aHR 2.05 vs. 1.82; both p<0.001) and all-cause mortality (aHR 1.63 vs. 1.43; both p<0.001). In KNHIS, clinical obesity showed consistent associations with liver-related events (aHR 1.36, 1.28–1.44; p<0.001) and cardiovascular events (aHR 1.25, 1.23–1.27; p<0.001), whereas mortality associations differed from UKBB, likely reflecting age-modified relationships. Among 90,386 UKBB participants with preclinical obesity at baseline, 33,434 (37%) progressed to clinical obesity with a median transition time of 8.0 years. Conclusions The Lancet Commission obesity classification refines longitudinal risk stratification beyond BMI-defined obesity, particularly for liver-related and cardiovascular outcomes, by identifying both a high-risk clinical obesity group and an intermediate preclinical stage. Preclinical obesity is a dynamic condition with substantial progression to clinical obesity, highlighting a potential window for early intervention in people at metabolic risk.

제목
Clinical Obesity Refines Longitudinal Risk Stratification for Liver-related and Cardiometabolic Outcomes Beyond BMI
저자
Pugliese, Nicola; Cesaro, Arturo; Flagiello, Valentina; Jamialahmadi, Oveis; Calabro, Paolo; Jeong, Seogsong; Mancina, Rosellina M.; Khil, Jaewon; Kim, Won; Mingrone, Geltrude; Vespasiani-Gentilucci, Umberto; Aghemo, Alessio; Romeo, Stefano
DOI
10.1016/j.dld.2026.07.035
발행일
2026-09
학회명
AISF Monothematic Conference 2026 – MASLD 2026: Redefining Metabolic Liver Disease
개최지
Palermo, Italy
개최국가
이탈리아
학회 개최일
2026-09-16 ~ 2026-09-25